Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF

Further analysis of the PARAGON trial also suggest the benefit of the drug combination may reach higher ejection fractions in women.Medscape Medical News

Source: Medscape Cardiology Headlines - November 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news